Overview
Around the holiday, insurers’ capital top-up wave kept heating up. Per Securities Times, five insurers disclosed capital-increase plans since September and 13 year-to-date; with bond issuance, combined debt and equity fundraising has exceeded 65 billion yuan. Guobao Life plans to issue 2.541 billion new shares for 3.075 billion yuan; China Merchants Renhe Life seeks 2.656 billion yuan; Junlong and Guofu among others follow.
The bond side is active too: 16 insurers secured approval for ~38.2 billion yuan of bonds or capital increases this year, of which perpetual bonds reached 24.7 billion (68.5%), the most favored instrument.
Background & Interpretation
1. Regulatory and Industry Context
The key variable is the formal end of the “Solvency II Phase II” transition at end-2025; from 2026, non-listed insurers’ solvency reports fully adopt the new rules. The rules raise risk factors for unlisted equity and real estate and strictly cap future earnings counted into core capital, pressuring industry core capital.
2. Core Drivers and Mechanisms
The driver is the low-rate environment: the 10-year CGB yield center fell to ~1.8%, while life insurers’ three-year rolling financial yield is only ~3.2%; legacy high-guaranteed policies’ liability costs are sticky, so the asset-liability “scissors gap” erodes net assets. Falling reserve discount rates force more reserves, burning capital on multiple fronts.
3. Market Structure and Industrial Chain Effects
By Q2 end, five insurers were below solvency thresholds, some near the 120% focus line. Top insurers (PICC Life, New China Life each approved 10B perpetual bonds) finance cheaply on rating strength; smaller insurers feel greater urgency yet face tighter external capital as profit expectations cool.
Implications & Outlook
Near term, falling perpetual-bond coupons (some below 2%) make issuance attractive; medium term, capital replenishment shifts from “emergency” to “routine prudence”, with equity and debt proceeding in parallel.
Takeaways for Industry Participants
- Insurers: seize the low-rate issuance window; optimize core vs. supplementary capital.
- Investors: watch “5+N” call and write-down clauses; track core solvency ratios.
- Regulators: balance adequacy with smaller insurers’ funding access.
This column compiles industry information and shares technical perspectives; it does not constitute investment advice.